title: Failure of desmopressin to lower serum sodium or prevent crisis in patients with sickle cell anemia.
abstract: An analogue of arginine vasopressin (desmopressin, DDAVP) was evaluated for production chronic hyponatremia and prevention of sickle cell crisis. With sodium restriction (100 meq Na + / day) and water loading ( greater than 3 liters/day), persistent hyponatremia could not be achieved, nor could crises be prevented or aborted. Patients would not comply with a regimen of lower salt and higher fluid intake. More rigorous treatment might be practical during acute sickle cell crises, and a regimen similar to that used here might be more effective in children, whose renal concentrating mechanisms are still intact.
mesh_terms: D000328:Adult; D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004905:Erythrocyte Aging; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy; D008297:Male; D009994:Osmolar Concentration; D010146:Pain / Q000209:etiology; D012964:Sodium / Q000097:blood*; D014556:Urine / Q000032:analysis
chemical_list: D001127:Arginine Vasopressin; D012964:Sodium; D003894:Deamino Arginine Vasopressin